Literature DB >> 6101957

Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease.

J M Day, J B Houston.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6101957      PMCID: PMC1429913          DOI: 10.1111/j.1365-2125.1980.tb04802.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  8 in total

1.  THE BINDING OF SULFONAMIDE DRUGS BY PLASMA PROTEINS. A FACTOR IN DETERMINING THE DISTRIBUTION OF DRUGS IN THE BODY.

Authors:  B D Davis
Journal:  J Clin Invest       Date:  1943-09       Impact factor: 14.808

Review 2.  Therapeutic drug monitoring in saliva.

Authors:  M Danhof; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

3.  High-performance liquid chromatographic determination of aminosalicylate, sulfapyridine and their metabolites. Its application for pharmacokinetic studies with salicylazosulfapyridine in man.

Authors:  C Fischer; U Klotz
Journal:  J Chromatogr       Date:  1979-02-21

4.  Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine.

Authors:  T R Bates; H P Blumenthal; H J Pieniaszek
Journal:  Clin Pharmacol Ther       Date:  1977-12       Impact factor: 6.875

5.  Active therapeutic moiety of sulphasalazine.

Authors:  P A van Hees; J H van Tongeren; J H Bakker; H J van Lier
Journal:  Lancet       Date:  1978-02-04       Impact factor: 79.321

6.  Determination of sulphapyridine and its metabolites in biological materials after administration of salicylazosulphapyridine.

Authors:  K A Hansson; M Sandberg
Journal:  Acta Pharm Suec       Date:  1973-03

Review 7.  Clinical pharmacokinetics of sulphasalazine.

Authors:  K M Das; R Dubin
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

8.  An experiment to determine the active therapeutic moiety of sulphasalazine.

Authors:  A K Azad Khan; J Piris; S C Truelove
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321

  8 in total
  2 in total

1.  Azo reduction of sulphasalazine in healthy volunteers.

Authors:  J B Houston; J Day; J Walker
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

2.  Acetylator phenotype and serum levels of sulfapyridine in patients with inflammatory bowel disease.

Authors:  M E Sharp; S M Wallace; K W Hindmarsh; M A Brown
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.